FBInvestor
Stocks / Lineage Cell Therapeutics In
Institutional Ownership

Lineage Cell Therapeutics In

CUSIP 53566P109COMLCTXQ1 2026

13D / 13G Filings
14
Schedule 13D/13G on record
Beneficial Filers
4
Distinct reporting persons
Largest Stake
24.5%
Max % of class reported
Institutional Holders
127
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

14 filings · latest Nov 14, 2025

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Nov 14, 2025Broadwood Partners, L.P.13D/A23.1%SEC
2Sep 26, 2025Chernett Jorey13G5.0%11.45MSEC
3Jul 17, 2025Blackrock, Inc.13G/A1.0%2.23MSEC
4Apr 24, 2025Blackrock, Inc.13G5.0%11.45MSEC
5Feb 5, 2025Blackrock, Inc.13G/A4.6%10.09MSEC
6Jan 28, 2025Broadwood Partners, L.P.13D/A24.5%SEC
7Nov 21, 2024Broadwood Partners, L.P.13D/A18.9%41.67MSEC
8Nov 8, 2024Blackrock, Inc.13G5.3%9.92MSEC
9Oct 22, 2024Blackrock, Inc.13G5.3%9.92MSEC
10Feb 8, 2024Broadwood Partners, L.P.13D/A22.1%41.67MSEC

4 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Lineage Cell Therapeutics In.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →